

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/085,322	02/28/2002	Abbot F. Clark	1910	8526	
7	590 01/04/2006	EXAMINER			
Alcon, Inc.			ZEMAN, ROBERT A		
c/o Alcon Rese Patrick M. Rva	arch, Ltd. n(Q-148), R&D Councel	ART UNIT	PAPER NUMBER		
6201 So. Freeway			1645		
Fort Worth, T	X 76134-2099		DATE MAILED: 01/04/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application No.		Applicant(s)			
Office Action Summary			10/085,322		CLARK, ABBOT F.			
			Examiner		Art Unit			
			Robert A. Zeman		1645			
Period fo	The MAILING DATE of this commun or Reply	ication appe	ars on the cover	sheet with the co	orrespondence ad	ddress		
WHI( - Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comp period for reply is specified above, the maximum st re to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DAT s of 37 CFR 1.136 nunication. atutory period will will, by statute, ca	TE OF THIS CON  (a). In no event, howevel  apply and will expire Solution to least the application the application to least the application the appl	MMUNICATION rer, may a reply be time IX (6) MONTHS from the become ABANDONED	l. ely filed the mailing date of this o O (35 U.S.C. § 133).			
Status								
1)	Responsive to communication(s) file	ed on 28 Feb	oruary 2002.					
2a)□	·		action is non-final	l.				
3)□								
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)⊠	Claim(s) 1-10 is/are pending in the	application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)□	Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)🖂	Claim(s) $\underline{1-10}$ are subject to restricti	on and/or ele	ection requireme	nt.				
Applicat	on Papers							
9)[	The specification is objected to by th	e Examiner.						
10)	The drawing(s) filed on is/are	: a) <u>□</u> accep	oted or b) 🔲 obje	cted to by the E	xaminer.			
	Applicant may not request that any obje	ction to the dr	awing(s) be held in	n abeyance. See	37 CFR 1.85(a).			
	Replacement drawing sheet(s) including	g the correctio	n is required if the	drawing(s) is obj	ected to. See 37 C	FR 1.121(d).		
11)	The oath or declaration is objected to	o by the Exa	miner. Note the	attached Office	Action or form P	TO-152.		
Priority (	ınder 35 U.S.C. § 119							
-	Acknowledgment is made of a claim  ☐ All b)☐ Some * c)☐ None of:	for foreign p	riority under 35 l	J.S.C. § 119(a)	-(d) or (f).			
a)	1.☐ Certified copies of the priority	documente	have been receiv	hav				
	2. Certified copies of the priority				nn No			
	3. Copies of the certified copies					l Stane		
	application from the Internation	· ·	-		d III diiis i vadoriai	Clage		
* 5	See the attached detailed Office action		•	•	d.			
`	. 12 mg amating detailed a mad detail		23 30					
Attachmen	r(c)							
_	e of References Cited (PTO-892)		41 🗆 11	nterview Summary (	(PTO-413)			
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (F	•	_ P	Paper No(s)/Mail Da	te			
	nation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date	PTO/SB/08)	· —	Notice of Informal Pa Other:	atent Application (PT	O-152)		

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-10, drawn to methods of treating a patient with an ophthalmic disease caused by a mutation in the gene GLC1A utilizing an aminoglycoside antibiotic

compound, classified in class 514, subclass 912.

II. Claims 1-10, drawn to methods of treating a patient with an ophthalmic disease

caused by a mutation in the gene CYP1B1 utilizing an aminoglycoside antibiotic

compound, classified in class 514, subclass 912.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are each separate and distinct from each other as they are drawn to differing methods having different steps, different goals and leading to differing results.

Because these inventions are distinct for the reasons given above and the search required for the various groups would not be coextensive in scope, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/085,322

Art Unit: 1645

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 3

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday - Thursday 7 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>.

Art Unit: 1645

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ROBERT A. ZEMAN PATENT EXAMINER

December 27, 2005